Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer ; volume:21 ; number:1 ; day:15 ; month:11 ; year:2023 ; pages:1-12 ; date:12.2023
Journal of translational medicine ; 21, Heft 1 (15.11.2023), 1-12, 12.2023
- Creator
-
Omar, Mohamed
Nuzzo, Pier Vitale
Ravera, Francesco
Bleve, Sara
Fanelli, Giuseppe Nicolò
Zanettini, Claudio
Valencia, Itzel
Marchionni, Luigi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-023-04713-3
- URN
-
urn:nbn:de:101:1-2024013111274684361282
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Omar, Mohamed
- Nuzzo, Pier Vitale
- Ravera, Francesco
- Bleve, Sara
- Fanelli, Giuseppe Nicolò
- Zanettini, Claudio
- Valencia, Itzel
- Marchionni, Luigi
- SpringerLink (Online service)
Other Objects (12)
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
Application of mammography-based radiomics signature for preoperative prediction of triple-negative breast cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer
Application of mammography-based radiomics signature for preoperative prediction of triple-negative breast cancer
Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer
A Minimal lncRNA-mRNA Signature Predicts Sensitivity to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Evaluation of neoadjuvant chemotherapy for clinical T1 triple-negative breast cancer
A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
Correction to: Co‑clinical FDG‑PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple‑negative breast cancer
The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer
The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Escalation of neoadjuvant therapy in triple-negative breast cancer—balancing effectiveness and toxicities
Gene expression signature for predicting homologous recombination deficiency in triple-negative breast cancer
Metastatic Triple-Negative Breast Cancer
An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer